What to expect from HER-2 directed therapies in advanced gastric cancer?

被引：1
|
作者：
Dane, Faysal [1 ]
机构：
[1] Marmara Univ, Sch Med, Dept Internal Med, Div Med Oncol, Mimar Sinan Caddesi 41 Ust Kaynarca Fevzicakmak M, Istanbul, Turkey
来源：
MARMARA MEDICAL JOURNAL | 2015年 / 28卷 / 04期
关键词：
Gastric cancer; HER-2/neu; Targeted therapy;
D O I：
10.5472/mmj.87204
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Gastric cancer is the second most common cause of cancer related death worldwide. Over 20% of the advanced gastric cancer are considered to be HER-2 positive. Studies investigating the prognosis of HER-2 positive advanced gastric cancer revealed conflicting results. Trastuzumab, a monoclonal antibody against HER-2, has shown a significant clinical activity in HER-2 positive gastric cancer patients. In this review, I will briefly summarize the clinical studies of anti-HER-2 therapies performed in HER-2 positive gastric carcinoma.
引用
收藏
页码：11 / 15
页数：5
相关论文
共 50 条
  • [21] Overexpression of Her-2 upregulates FoxM1 in gastric cancer
    Qi, Weiwei
    Li, Xiaoxiao
    Zhang, Yongchun
    Yao, Ruyong
    Qiu, Wensheng
    Tang, Dongfang
    Liang, Jun
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 33 (06) : 1531 - 1538
  • [22] Clinicopathologic significance of Her-2 and P53 expressions in gastric cancer
    Zhang, Xiaoyu
    Wang, Mingchuan
    Wang, Yizhuo
    Cheng, Xianbin
    Jiang, Yang
    Xiao, Huijie
    ASIAN JOURNAL OF SURGERY, 2023, 46 (01) : 526 - 531
  • [23] History and Future of HER2-Targeted Therapy for Advanced Gastric Cancer
    Ariga, Shin
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (10)
  • [24] Targeted Therapies in Advanced Gastric Cancer
    Timil H. Patel
    Michael Cecchini
    Current Treatment Options in Oncology, 2020, 21
  • [25] Downregulation of NPM expression by Her-2 reduces resistance of gastric cancer to oxaliplatin
    Sun, Zhenni
    Yue, Lu
    Shen, Zan
    Li, Yong
    Sui, Aihua
    Li, Tianjun
    Tang, Qian
    Yao, Ruyong
    Sun, Yongning
    ONCOLOGY LETTERS, 2017, 13 (04) : 2377 - 2384
  • [26] The clinical significance of HER-2 and NF-κB expression in Gastric Cancer
    Li, Xiaogai
    Tu, Jiancheng
    Zhang, Di
    Xu, Zhigao
    Yang, Guifang
    Gong, Lingling
    Yu, Mingxia
    HEPATO-GASTROENTEROLOGY, 2013, 60 (126) : 1519 - 1523
  • [27] HER-2 incidence in gastric cancer, its association with prognosis and clinicopathological parameters
    Uprak, Tevfik Kivilcim
    Attaallah, Wafi
    Celikel, Cigdem Ataizi
    Ayranci, Gulcicek
    Yegen, Cumhur
    TURKISH JOURNAL OF SURGERY, 2015, 31 (04) : 207 - 213
  • [28] HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients
    Halon, Agnieszka
    Donizy, Piotr
    Biecek, Przemyslaw
    Rudno-Rudzinska, Julia
    Kielan, Wojciech
    Matkowski, Rafal
    SCIENTIFIC WORLD JOURNAL, 2012,
  • [29] Frequency of HER-2 Positivity in Rectal Cancer and Prognosis
    Conradi, Lena-Christin
    Styczen, Hanna
    Sprenger, Thilo
    Wolff, Hendrik A.
    Roedel, Claus
    Nietert, Manuel
    Homayounfar, Kia
    Gaedcke, Jochen
    Kitz, Julia
    Talaulicar, Recca
    Becker, Heinz
    Ghadimi, Michael
    Middel, Peter
    Beissbarth, Tim
    Rueschoff, Josef
    Liersch, Torsten
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2013, 37 (04) : 522 - 531
  • [30] RETRACTED: Correlations of β-catenin, Ki67 and Her-2/neu with gastric cancer (Retracted Article)
    Wu, Hong-Wen
    Qin, Cheng-Yong
    Huang, Ji-Lai
    Kong, Xian-Yi
    Wang, Wen-Ji
    Bai, Wen-Kun
    ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, 2014, 7 (04) : 257 - 261
12345